Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia

Background Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this ag...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2021-07, Vol.68 (7), p.e28940-n/a
Hauptverfasser: Ibrahimova, Azada, Winestone, Lena E., Miller, Tamara P., Kettler, Kyle, Seif, Alix E., Huang, Yuan‐Shung, Elgarten, Caitlin W., Myers, Regina M., Fisher, Brian T., Aplenc, Richard, Getz, Kelly D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 7
container_start_page e28940
container_title Pediatric blood & cancer
container_volume 68
creator Ibrahimova, Azada
Winestone, Lena E.
Miller, Tamara P.
Kettler, Kyle
Seif, Alix E.
Huang, Yuan‐Shung
Elgarten, Caitlin W.
Myers, Regina M.
Fisher, Brian T.
Aplenc, Richard
Getz, Kelly D.
description Background Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group. Methods In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis. Results Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants. Conclusions Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.
doi_str_mv 10.1002/pbc.28940
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8283996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2533602033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhoNYbK1e-AdkwBsLbpuv2UluCrr4USjYC70OJ8kZmzofa5KxbH-92Z26aKEQSDh58nBOXkJeMXrKKOVna-tOudKSPiFHrJb1oqasebo_U31Inqd0U9AlrdUzcihEQ6Vm7IjAVcSEQ4YcxqECN4W8eVeFwU9uV-nHmKHbFWHwVYHHKTqsphy6cDe_CtvVwpBTdRvy9daSsepw-ol9gBfkoIUu4cv7_Zh8__Tx2-rL4vLr54vV-8uFk1LQxbIGJa1iQJWqQUvtGgDJLLdW-VZ7qzhHDp4jtl6gQ914iQ0wSz1z3opjcj5715Pt0bsyVITOrGPoIW7MCMH8fzOEa_Nj_G0UV0LrZRG8vRfE8deEKZs-JIddBwOOUzK8_KRoasFZQd88QG_KtwxlvEIJsaScClGok5lycUwpYrtvhlGzDc6U4MwuuMK-_rf7Pfk3qQKczcBt6HDzuMlcfVjNyj-iVaVh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2533602033</pqid></control><display><type>article</type><title>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ibrahimova, Azada ; Winestone, Lena E. ; Miller, Tamara P. ; Kettler, Kyle ; Seif, Alix E. ; Huang, Yuan‐Shung ; Elgarten, Caitlin W. ; Myers, Regina M. ; Fisher, Brian T. ; Aplenc, Richard ; Getz, Kelly D.</creator><creatorcontrib>Ibrahimova, Azada ; Winestone, Lena E. ; Miller, Tamara P. ; Kettler, Kyle ; Seif, Alix E. ; Huang, Yuan‐Shung ; Elgarten, Caitlin W. ; Myers, Regina M. ; Fisher, Brian T. ; Aplenc, Richard ; Getz, Kelly D.</creatorcontrib><description>Background Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group. Methods In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis. Results Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants. Conclusions Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.28940</identifier><identifier>PMID: 33704911</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acuity ; Acute myeloid leukemia ; Anthracycline ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Child ; Children ; Diuretics ; Hematology ; Hospitals, Pediatric ; Humans ; induction mortality ; Infant ; infant leukemia ; Infants ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Lymphatic leukemia ; Mortality ; Multiple organ dysfunction syndrome ; Myeloid leukemia ; Oncology ; Pediatrics ; Resource utilization ; Retrospective Studies</subject><ispartof>Pediatric blood &amp; cancer, 2021-07, Vol.68 (7), p.e28940-n/a</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</citedby><cites>FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</cites><orcidid>0000-0003-2020-5153</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.28940$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.28940$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33704911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ibrahimova, Azada</creatorcontrib><creatorcontrib>Winestone, Lena E.</creatorcontrib><creatorcontrib>Miller, Tamara P.</creatorcontrib><creatorcontrib>Kettler, Kyle</creatorcontrib><creatorcontrib>Seif, Alix E.</creatorcontrib><creatorcontrib>Huang, Yuan‐Shung</creatorcontrib><creatorcontrib>Elgarten, Caitlin W.</creatorcontrib><creatorcontrib>Myers, Regina M.</creatorcontrib><creatorcontrib>Fisher, Brian T.</creatorcontrib><creatorcontrib>Aplenc, Richard</creatorcontrib><creatorcontrib>Getz, Kelly D.</creatorcontrib><title>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</title><title>Pediatric blood &amp; cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Background Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group. Methods In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis. Results Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants. Conclusions Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.</description><subject>Acuity</subject><subject>Acute myeloid leukemia</subject><subject>Anthracycline</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Child</subject><subject>Children</subject><subject>Diuretics</subject><subject>Hematology</subject><subject>Hospitals, Pediatric</subject><subject>Humans</subject><subject>induction mortality</subject><subject>Infant</subject><subject>infant leukemia</subject><subject>Infants</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Lymphatic leukemia</subject><subject>Mortality</subject><subject>Multiple organ dysfunction syndrome</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Resource utilization</subject><subject>Retrospective Studies</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1rFDEUhoNYbK1e-AdkwBsLbpuv2UluCrr4USjYC70OJ8kZmzofa5KxbH-92Z26aKEQSDh58nBOXkJeMXrKKOVna-tOudKSPiFHrJb1oqasebo_U31Inqd0U9AlrdUzcihEQ6Vm7IjAVcSEQ4YcxqECN4W8eVeFwU9uV-nHmKHbFWHwVYHHKTqsphy6cDe_CtvVwpBTdRvy9daSsepw-ol9gBfkoIUu4cv7_Zh8__Tx2-rL4vLr54vV-8uFk1LQxbIGJa1iQJWqQUvtGgDJLLdW-VZ7qzhHDp4jtl6gQ914iQ0wSz1z3opjcj5715Pt0bsyVITOrGPoIW7MCMH8fzOEa_Nj_G0UV0LrZRG8vRfE8deEKZs-JIddBwOOUzK8_KRoasFZQd88QG_KtwxlvEIJsaScClGok5lycUwpYrtvhlGzDc6U4MwuuMK-_rf7Pfk3qQKczcBt6HDzuMlcfVjNyj-iVaVh</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Ibrahimova, Azada</creator><creator>Winestone, Lena E.</creator><creator>Miller, Tamara P.</creator><creator>Kettler, Kyle</creator><creator>Seif, Alix E.</creator><creator>Huang, Yuan‐Shung</creator><creator>Elgarten, Caitlin W.</creator><creator>Myers, Regina M.</creator><creator>Fisher, Brian T.</creator><creator>Aplenc, Richard</creator><creator>Getz, Kelly D.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2020-5153</orcidid></search><sort><creationdate>202107</creationdate><title>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</title><author>Ibrahimova, Azada ; Winestone, Lena E. ; Miller, Tamara P. ; Kettler, Kyle ; Seif, Alix E. ; Huang, Yuan‐Shung ; Elgarten, Caitlin W. ; Myers, Regina M. ; Fisher, Brian T. ; Aplenc, Richard ; Getz, Kelly D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4430-65a84b81a0885a949c7aa41b2bb8df9db822e2ad2eefd3ece97d4e7a1b0d1cdb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acuity</topic><topic>Acute myeloid leukemia</topic><topic>Anthracycline</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Child</topic><topic>Children</topic><topic>Diuretics</topic><topic>Hematology</topic><topic>Hospitals, Pediatric</topic><topic>Humans</topic><topic>induction mortality</topic><topic>Infant</topic><topic>infant leukemia</topic><topic>Infants</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Lymphatic leukemia</topic><topic>Mortality</topic><topic>Multiple organ dysfunction syndrome</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Resource utilization</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ibrahimova, Azada</creatorcontrib><creatorcontrib>Winestone, Lena E.</creatorcontrib><creatorcontrib>Miller, Tamara P.</creatorcontrib><creatorcontrib>Kettler, Kyle</creatorcontrib><creatorcontrib>Seif, Alix E.</creatorcontrib><creatorcontrib>Huang, Yuan‐Shung</creatorcontrib><creatorcontrib>Elgarten, Caitlin W.</creatorcontrib><creatorcontrib>Myers, Regina M.</creatorcontrib><creatorcontrib>Fisher, Brian T.</creatorcontrib><creatorcontrib>Aplenc, Richard</creatorcontrib><creatorcontrib>Getz, Kelly D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood &amp; cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ibrahimova, Azada</au><au>Winestone, Lena E.</au><au>Miller, Tamara P.</au><au>Kettler, Kyle</au><au>Seif, Alix E.</au><au>Huang, Yuan‐Shung</au><au>Elgarten, Caitlin W.</au><au>Myers, Regina M.</au><au>Fisher, Brian T.</au><au>Aplenc, Richard</au><au>Getz, Kelly D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia</atitle><jtitle>Pediatric blood &amp; cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2021-07</date><risdate>2021</risdate><volume>68</volume><issue>7</issue><spage>e28940</spage><epage>n/a</epage><pages>e28940-n/a</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Background Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group. Methods In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis. Results Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants. Conclusions Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33704911</pmid><doi>10.1002/pbc.28940</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2020-5153</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1545-5009
ispartof Pediatric blood & cancer, 2021-07, Vol.68 (7), p.e28940-n/a
issn 1545-5009
1545-5017
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8283996
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Acuity
Acute myeloid leukemia
Anthracycline
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Child
Children
Diuretics
Hematology
Hospitals, Pediatric
Humans
induction mortality
Infant
infant leukemia
Infants
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Lymphatic leukemia
Mortality
Multiple organ dysfunction syndrome
Myeloid leukemia
Oncology
Pediatrics
Resource utilization
Retrospective Studies
title Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A56%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Presentation%20acuity,%20induction%20mortality,%20and%20resource%20utilization%20in%20infants%20with%20acute%20leukemia&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Ibrahimova,%20Azada&rft.date=2021-07&rft.volume=68&rft.issue=7&rft.spage=e28940&rft.epage=n/a&rft.pages=e28940-n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.28940&rft_dat=%3Cproquest_pubme%3E2533602033%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2533602033&rft_id=info:pmid/33704911&rfr_iscdi=true